PortfoliosLab logo
VIR vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between VIR and RXRX is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

VIR vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

-90.00%-85.00%-80.00%-75.00%-70.00%-65.00%NovemberDecember2025FebruaryMarchApril
-86.80%
-81.69%
VIR
RXRX

Key characteristics

Sharpe Ratio

VIR:

-0.28

RXRX:

-0.28

Sortino Ratio

VIR:

0.14

RXRX:

0.18

Omega Ratio

VIR:

1.02

RXRX:

1.02

Calmar Ratio

VIR:

-0.26

RXRX:

-0.28

Martin Ratio

VIR:

-0.73

RXRX:

-0.82

Ulcer Index

VIR:

33.68%

RXRX:

31.21%

Daily Std Dev

VIR:

89.54%

RXRX:

91.10%

Max Drawdown

VIR:

-93.75%

RXRX:

-90.39%

Current Drawdown

VIR:

-92.63%

RXRX:

-86.14%

Fundamentals

Market Cap

VIR:

$868.42M

RXRX:

$2.31B

EPS

VIR:

-$3.83

RXRX:

-$1.69

PS Ratio

VIR:

11.70

RXRX:

39.28

PB Ratio

VIR:

0.73

RXRX:

2.23

Total Revenue (TTM)

VIR:

$16.73M

RXRX:

$45.01M

Gross Profit (TTM)

VIR:

$11.69M

RXRX:

$7.04M

EBITDA (TTM)

VIR:

-$462.00M

RXRX:

-$342.94M

Returns By Period

In the year-to-date period, VIR achieves a -16.62% return, which is significantly lower than RXRX's -15.24% return.


VIR

YTD

-16.62%

1M

-8.66%

6M

-18.18%

1Y

-25.64%

5Y*

-28.58%

10Y*

N/A

RXRX

YTD

-15.24%

1M

-1.38%

6M

-11.57%

1Y

-29.43%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VIR vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VIR
The Risk-Adjusted Performance Rank of VIR is 3838
Overall Rank
The Sharpe Ratio Rank of VIR is 3737
Sharpe Ratio Rank
The Sortino Ratio Rank of VIR is 4141
Sortino Ratio Rank
The Omega Ratio Rank of VIR is 4141
Omega Ratio Rank
The Calmar Ratio Rank of VIR is 3535
Calmar Ratio Rank
The Martin Ratio Rank of VIR is 3636
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 3838
Overall Rank
The Sharpe Ratio Rank of RXRX is 3737
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 4242
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 4242
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 3434
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 3434
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VIR vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for VIR, currently valued at -0.28, compared to the broader market-2.00-1.000.001.002.003.00
VIR: -0.28
RXRX: -0.28
The chart of Sortino ratio for VIR, currently valued at 0.14, compared to the broader market-6.00-4.00-2.000.002.004.00
VIR: 0.14
RXRX: 0.18
The chart of Omega ratio for VIR, currently valued at 1.02, compared to the broader market0.501.001.502.00
VIR: 1.02
RXRX: 1.02
The chart of Calmar ratio for VIR, currently valued at -0.27, compared to the broader market0.001.002.003.004.005.00
VIR: -0.27
RXRX: -0.28
The chart of Martin ratio for VIR, currently valued at -0.73, compared to the broader market-5.000.005.0010.0015.0020.00
VIR: -0.73
RXRX: -0.82

The current VIR Sharpe Ratio is -0.28, which is comparable to the RXRX Sharpe Ratio of -0.28. The chart below compares the historical Sharpe Ratios of VIR and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.60-0.40-0.200.000.200.400.60NovemberDecember2025FebruaryMarchApril
-0.28
-0.28
VIR
RXRX

Dividends

VIR vs. RXRX - Dividend Comparison

Neither VIR nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

VIR vs. RXRX - Drawdown Comparison

The maximum VIR drawdown since its inception was -93.75%, roughly equal to the maximum RXRX drawdown of -90.39%. Use the drawdown chart below to compare losses from any high point for VIR and RXRX. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%NovemberDecember2025FebruaryMarchApril
-88.78%
-86.14%
VIR
RXRX

Volatility

VIR vs. RXRX - Volatility Comparison

The current volatility for Vir Biotechnology, Inc. (VIR) is 21.97%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 37.94%. This indicates that VIR experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%NovemberDecember2025FebruaryMarchApril
21.97%
37.94%
VIR
RXRX

Financials

VIR vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items